These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening. Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272 [TBL] [Abstract][Full Text] [Related]
3. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Pasanen A; Loukovaara M; Bützow R Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377 [TBL] [Abstract][Full Text] [Related]
9. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759 [TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer]. Jin W; Wang LQ; Liu Y; Liu AJ Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020 [No Abstract] [Full Text] [Related]
11. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry. Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542 [TBL] [Abstract][Full Text] [Related]
12. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123 [TBL] [Abstract][Full Text] [Related]
13. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer. Loukovaara M; Pasanen A; Bützow R Cancer Med; 2021 Feb; 10(3):1034-1042. PubMed ID: 33449452 [TBL] [Abstract][Full Text] [Related]
14. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer. Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ Front Immunol; 2019; 10():3023. PubMed ID: 31998307 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264 [TBL] [Abstract][Full Text] [Related]
16. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics. Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India. Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922 [TBL] [Abstract][Full Text] [Related]
18. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076 [TBL] [Abstract][Full Text] [Related]
19. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Lajkosz K; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh T; Pollett A; Ferguson SE Gynecol Oncol; 2021 Apr; 161(1):221-227. PubMed ID: 33478752 [TBL] [Abstract][Full Text] [Related]
20. Endometrial Cancer Characteristics and Risk of Recurrence. Borden LE; Locklear TM; Grider DJ; Osborne JL; Saks EJ; Valea FA; Iglesias DA Am J Clin Pathol; 2022 Jan; 157(1):90-97. PubMed ID: 34463332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]